L
Luigi D. Notarangelo
Researcher at National Institutes of Health
Publications - 121
Citations - 9456
Luigi D. Notarangelo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Severe combined immunodeficiency & Immunodeficiency. The author has an hindex of 51, co-authored 121 publications receiving 8872 citations. Previous affiliations of Luigi D. Notarangelo include University of Brescia.
Papers
More filters
Journal ArticleDOI
X-Linked Lymphoproliferative Disease 2b4 Molecules Displaying Inhibitory Rather than Activating Function Are Responsible for the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected Cells
Silvia Parolini,Cristina Bottino,Michela Falco,Raffaella Augugliaro,Silvia Giliani,Roberta Franceschini,Hans D. Ochs,Hermann M. Wolf,Jean Yves Bonnefoy,Roberto Biassoni,Lorenzo Moretta,Luigi D. Notarangelo,Alessandro Moretta +12 more
TL;DR: It is shown that, in patients with X-linked lymphoproliferative disease (XLP), a severe inherited immunodeficiency characterized by critical mutations in the SH2D1A gene and by the inability to control Epstein-Barr virus infections, 2B4 not only fails to transduce triggering signals, but also mediates a sharp inhibition of the NK-mediated cytolysis.
Journal ArticleDOI
Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?
Andrew R. Gennery,Andrew R. Gennery,Mary Slatter,Mary Slatter,Laure Grandin,Pierre Taupin,Andrew J. Cant,Paul Veys,Persis Amrolia,H. Bobby Gaspar,E. Graham Davies,Wilhelm Friedrich,Manfred Hoenig,Luigi D. Notarangelo,Evelina Mazzolari,Fulvio Porta,Robbert G. M. Bredius,A.C. Lankester,Nico M Wulffraat,Reinhard Seger,Tayfun Güngör,Anders Fasth,Petr Sedlacek,Bénédicte Neven,Stéphane Blanche,Alain Fischer,Marina Cavazzana-Calvo,Paul Landais +27 more
TL;DR: Individual disease categories now need to be analyzed so that disease-specific prognosis may be better understood and the best treatments planned, despite improvements in each group.
Journal ArticleDOI
Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM
Simona Ferrari,Silvia Giliani,Antonella Insalaco,Abdulaziz Al-Ghonaium,Anna Rosa Soresina,Michael Loubser,Maria Antonietta Avanzini,M. Marconi,Raffaele Badolato,Alberto G. Ugazio,Yves Levy,Nadia Catalan,Anne Durandy,Abdelghani Tbakhi,Luigi D. Notarangelo,Alessandro Plebani +15 more
TL;DR: Findings show that mutations of the CD40 gene cause an autosomal recessive form of hyper IgM, which is immunologically and clinically undistinguishable from the X-linked form.
Journal ArticleDOI
Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected B Cells in X-Linked Lymphoproliferative Disease
Cristina Bottino,Michela Falco,Silvia Parolini,Emanuela Marcenaro,Raffaella Augugliaro,Simona Sivori,Elena Landi,Roberto Biassoni,Luigi D. Notarangelo,Lorenzo Moretta,Lorenzo Moretta,Alessandro Moretta +11 more
TL;DR: Analysis of NK cells derived from patients with X-linked lymphoproliferative disease (XLP) showed that the lack of SH2D1A protein profoundly affects the function not only of 2B4 but also of NTB-A, which appears to play an important role in the inability of XLP-NK cells to kill EBV-infected target cells.
Journal ArticleDOI
V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations.
Anna Villa,Cristina Sobacchi,Luigi D. Notarangelo,Fabio Bozzi,Mario Abinun,Tore G. Abrahamsen,Peter D. Arkwright,Michal Baniyash,Edward G. Brooks,Mary Ellen Conley,Patricia Cortes,Marzia Duse,Anders Fasth,Alexandra M. Filipovich,Anthony J. Infante,Alison L Jones,Evelina Mazzolari,Susanna M. Müller,Srdjan Pasic,Gideon Rechavi,Maria Grazia Sacco,Sandro Santagata,Marlis L. Schroeder,Reinhard Seger,Dario Strina,Alberto G. Ugazio,Jouni Väliaho,Mauno Vihinen,Larry B. Vogler,Hans D. Ochs,Paolo Vezzoni,Wilhelm Friedrich,Klaus Schwarz +32 more
TL;DR: The clinical and immunologic phenotypes of patients bearing mutations in RAGs are more diverse than previously thought and that this variability is related, in part, to the specific type of RAG mutation.